The launch time and indications of brigatinib/brigatinib in the country

Brigatinib/Brigatinib (Brigatinib) is a new generation of ALK (anaplastic lymphoma kinase) inhibitor that has attracted worldwide attention for its therapeutic value in ALK-positive non-small cell lung cancer (NSCLC). With the development of domestic lung cancer medicine, this drug has also completed the listing process in China. The original brigatinib drug was developed by an international pharmaceutical company and has been approved for marketing by the State Food and Drug Administration in China. The launch time is closely related to the accumulation of international clinical data and real-world demand. It is worth noting that the drug has been included in Category B of the National Medical Insurance List, providing more accessibility to patients with ALK-positive lung cancer. Especially in long-term treatment, medical insurance coverage reduces the financial burden on patients and promotes the adjustment of the domestic ALK-targeted drug market structure.

In terms of indications, brigatinib is mainly used for patients with ALK-positive advanced or metastatic non-small cell lung cancer, especially in cases of disease progression after previous treatment with crizotinib, showing obvious clinical advantages. Compared with first-generation ALK inhibitors, brigatinib has shown stronger activity in overcoming brain metastases and drug-resistant mutations, which is an important basis for its approval. With the popularization of accurate detection technology, ALK fusion gene detection has become part of the standardized diagnosis and treatment of advanced lung cancer, making the clinical use scope of brigatinib clearer.

In terms of specifications, the domestic market has provided a variety of dosage packaging forms, including30mg, 90mg and 180mg tablets, which facilitates doctors to adjust treatment plans according to the specific conditions of patients. Different specifications are also designed to meet the clinical needs of gradually increasing the administration of targeted drugs, which can not only ensure the efficacy, but also facilitate the observation and management of tolerance. Combined with medical insurance coverage and various dosage forms, brigatinib has gradually become one of the main treatment options for patients with ALK-positive lung cancer.

Reference materials:https://www.alunbrig.com/